EMMLF - EMMLF STOCK NEWS

OKYO Pharma announced the closing of its public offering of 625,000 American Depository Shares (ADSs) at $4.00 per share, totaling $2.5 million in gross proceeds. The funds will be utilized to advance the IND filing for OK-101 to treat dry eye disease (DED), support an initial Phase 2 clinical trial, and for general corporate purposes. ThinkEquity served as the sole book-running manager. This offering follows the effective registration statement filed with the SEC on May 16, 2022.

OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) announced that Panetta Partners Limited, associated with Executive Chairman Gabriele Cerrone, purchased 25,000 American Depository Shares (ADS) at $3.8749 each on May 17, 2022. This transaction increased Cerrone's beneficial interest from 39.52% to 39.64%. However, with an upcoming offering closing on May 19, 2022, his stake will be diluted to 38.50%. The ADS represents 65 ordinary shares, and the transaction occurred on NASDAQ.

OKYO Pharma Limited has announced the pricing of its underwritten initial public offering (IPO) of American Depositary Shares (ADSs) on the Nasdaq Capital Market. The company will issue 625,000 ADSs at $4.00 each, raising approximately $2.5 million in gross proceeds. The offering is expected to close on May 19, 2022. Funds will be used for advancing clinical trials and general corporate needs. The total number of Ordinary Shares after the offering will reach 1,415,040,468.

OKYO Pharma Limited has announced a public offering of 625,000 American Depositary Shares (ADSs) at $4.00 each, expected to raise approximately $2,500,000. An additional 93,750 ADSs may be purchased by underwriters to cover over-allotments. The offering is set to close on May 19, 2022, pending customary conditions. Proceeds will fund the IND filing for OK-101 targeting Dry Eye Disease (DED) and support an initial Phase 2 clinical trial. The ADSs will begin trading on Nasdaq under the symbol ‘OKYO’ from May 17, 2022.

OKYO Pharma Limited (OTCQB: EMMLF) announced presentations on drug candidates OK-101 and OK-201 at the ARVO Annual Meeting, taking place from May 1-4, 2022. The oral presentation will showcase the efficacy of OK-101 in reducing neuropathic corneal pain in a mouse model, while a poster session will detail OK-201's potential in alleviating similar pain. These findings were developed in collaboration with Dr. Pedram Hamrah at Tufts Medical Center. OKYO focuses on innovative treatments for ocular pain and inflammatory dry eye diseases.

OKYO Pharma Limited (OTCQB: EMMLF) has filed a registration statement with the SEC for a proposed initial public offering (IPO) of American Depositary Shares (ADSs) in the U.S. The size, number of shares, and pricing details for the offering are yet to be determined and will depend on market conditions. OKYO plans to list its ADSs on the Nasdaq under the symbol 'OKYO', while its Ordinary Shares will continue trading on the London Stock Exchange. The offering is managed by ThinkEquity, and securities cannot be sold until the registration statement becomes effective.

OKYO Pharma Limited (OTCQB: EMMLF) announced the issuance of U.S. Patent No. 11,254,720, covering key claims for OK-101, its lead pre-clinical compound designed to treat dry eye disease (DED) and neuropathic pain. The drug is expected to enter a Phase 2 clinical trial in Q4 2022, following a successful pre-IND meeting with the FDA. The potential of OK-101 lies in its dual ability to relieve ocular pain and inflammation, addressing significant unmet medical needs in DED patients.

OKYO Pharma Limited (OTCQB: EMMLF) announced the issuance of 403,719,360 new ordinary shares, fully paid from the conversion of all outstanding convertible loan notes and cashless exercise of warrants. This move simplifies the capital structure and eliminates all remaining debt, facilitating a dual listing on NASDAQ. The enlarged share capital will amount to 1,374,405,468 ordinary shares post-admission. Admission is expected to commence at 8:00 a.m. on February 24, 2022, following applications to the UK Financial Conduct Authority.

OKYO Pharma Limited (OTCQB: EMMLF) announced the successful completion of a pre-IND meeting with the FDA regarding its clinical development for OK-101 aimed at treating dry eye disease (DED). The FDA approved the trial's design, confirming the primary efficacy endpoints for the Phase 2 study. The company aims to initiate the trial in Q4 2022 and file for an NDA subsequently. OK-101 is a novel peptide designed to address inflammation and pain in the eye, potentially helping millions suffering from DED.